BioLineRx Ltd.'s BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences
5/2/2013 11:40:33 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that the Company was invited to deliver an oral presentation at the 2013 National Education Conference & Gluten-Free Expo, the Celiac Disease Foundation's annual conference, in Pasadena, California. Leah Klapper, Ph.D., General Manager, BioLine Innovations Jerusalem, will present BL-7010, for the treatment of celiac, as part of a session entitled Breaking Therapies Beyond the Gluten-Free Diet, that will take place on May 4.
Help employers find you! Check out all the jobs and post your resume.
comments powered by